Nanoform Launches Technology that can form Biological Nanoparticles as Small as 50 nm and New Near-Term Business Target for 2021

Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medication empowering organization, today reported a proprietary technology that can frame biological nanoparticles as small as 50 nm and declared another close term business focus for 2021 to convey its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

As drug molecules become more complex so do the alternatives to convey them. This complex nanoparticle formation technology gives want to improving the potential outcomes and probabilities of growing better medications for patients and it extends Nanoform's  reach into the growing biological market. The technology is in its beginning phases of advancement and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side notwithstanding the eight CESS® little atom nanoparticle innovation non-GMP lines.